PUBLIC COMPANY
save$GKOSGLAUKOS Corp
$GKOS184.89-2.46%Aliso Viejo, CA, USupdated 5h ago
community read0 votes
pipeline
13
marketed
1
phase 3
1
catalysts ytd
6
approvals ytd
2
recalls ytd
0
Pipeline(13)
view full pipeline →pipeline depth13 products
2Preclinical7Phase 21Phase 31Marketed2Unknown
Marketed
riboflavin 5'-phosphate sodium
Keratoconus
Phase 3travoprost ER
Ocular Hypertension
Prostaglandin F2-alpha receptor
Phase 2GLK-221
Keratoconus
Phase 2GLK-302
Presbyopia
Muscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3
Phase 2GLK-321
Demodex Blepharitis
Phase 2GLK-401
Age Related Macular Degeneration
Phase 2IVMED-80
Keratoconus
Phase 2iLution travoprost
Ocular Hypertension
Prostaglandin F2-alpha receptor
Phase 2pilocarpine
Keratoconjunctivitis Sicca (Dry Eye)
Muscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3
PreclinicaliDose Next Generation
Glaucoma
Preclinicaltriamcinolone acetonide SR
Diabetic Macular Edema
drugEPIOXA HD/EPIOXA KIT
keratoconus
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase4Travoprost Intraocular Implant + iStent Infinite
- phase3Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- phase3Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- phase2Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
- —Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
- phase2Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
- phase4Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
- phase2A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER−$144K↗
- Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER−$73K↗
- Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER−$25K↗
- Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER−$4K↗
- Mar 25, 26SELLThurman Alex R.· SVP & CHIEF FINANCIAL OFFICER−$267K↗
- Mar 24, 26SELLThurman Alex R.· SVP & CHIEF FINANCIAL OFFICER−$160K↗
- Mar 17, 26SELLThurman Alex R.· SVP & CHIEF FINANCIAL OFFICER−$62K↗
- Mar 16, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER−$45K↗
- Mar 16, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER−$29K↗
- Mar 16, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER−$27K↗
routine RSU / option mechanics (6)
- Apr 2, 26tax coverBurns Thomas William · CHAIRMAN & CEO7,468 sh
- Apr 2, 26tax coverGilliam Joseph E · PRESIDENT & COO3,169 sh
- Apr 2, 26tax coverBurns Thomas William · CHAIRMAN & CEO2,469 sh
- Apr 2, 26tax coverNavratil Tomas · CHIEF DEVELOPMENT OFFICER1,831 sh
- Apr 2, 26tax coverThurman Alex R. · SVP & CHIEF FINANCIAL OFFICER1,589 sh
- Apr 2, 26tax coverNavratil Tomas · CHIEF DEVELOPMENT OFFICER1,146 sh
🐶 Hiring Signal
next earnings Oct 28, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that